Purpose: This is a retrospective, comparative, head-to-head, not commissioned study about the efficacy of bimato-prost 0.03%, brimonidine 0.2%, brinzolamide 1%, dorzolamide 2%, and travoprost 0.004%/timolol 0.5%-fixed...Purpose: This is a retrospective, comparative, head-to-head, not commissioned study about the efficacy of bimato-prost 0.03%, brimonidine 0.2%, brinzolamide 1%, dorzolamide 2%, and travoprost 0.004%/timolol 0.5%-fixed combinations in patients affected by na?ve open-angle glaucoma and IOP > 25 mmHg. Patients and Methods: Files from 70 patients (35 M, 35 F, mean age 69.52 y, S.D. 11.56, range: 37-87y) in our Glaucoma Service were retrospectively analyzed as long as 12 months. Every subgroup, including 14 age- and sex-matched patients, was allocated to 1 of the 5 groups of the fixed combinations monotherapy. Data recorded after 3 months follow-up were statistically analyzed by descriptive and ANOVA statistics as percentage of IOP reduction from baseline. Results: All the fixed combinations were effective in lowering IOP. The mean percentage reduction was: brimonidine/timolol 43.57%, dorzolamide/timolol 37.67%, bimatoprost/timolol 35.60%, travoprost/timolol 33.25% and brinzolamide/timolol 23.0%. The brimonidine/timolol fixed combination showed to be statistically significant more effective only than brinzolamide/timolol fixed combination (p = 0.001). Setting the α error to 5%, the power of the study is 26%, phi: 0.842. Discussion: In all this cohort of patients the target IOP was successfully achieved. All the fixed combinations used in this study had a very good profile of efficacy. Brimonidine, dorzolamide, bimatoprost and travoprost/timolol fixed combinations statistically significantly reduced the percentage of IOP from baseline (p = 0.001) more than brinzolamide/timolol fixed combination.展开更多
A 38-year-old man with no history of uveitis developed neovascular glaucoma (NVG) due to proliferative diabetic retinopathy (PDR). He had a history of ocular surgery with placement of glaucoma drainage implants (GDI),...A 38-year-old man with no history of uveitis developed neovascular glaucoma (NVG) due to proliferative diabetic retinopathy (PDR). He had a history of ocular surgery with placement of glaucoma drainage implants (GDI), ultrasonic phacoemulsification, and intraocular lens implantation in both eyes. The patient had undergone a recent pars plana vitrectomy with complete panretinal photocoagulation (PRP) to clear vitreous hemorrhage in his right eye. To prevent progressive optic nerve damage, travoprost was tentatively administered because of inadequate intraocular pressure (IOP) control following surgery, laser treatment, and topical administration of many other IOP-lowering drugs. The patient experienced severe vision loss associated with acute anterior and intermediate uveitis. We consider it a rare complication due to the NVG patient’s vulnerability following ocular surgery. Given that acute uveitis developed rapidly and required time to resolve, systemic corticosteroid treatment could be considered to accelerate the resolution of inflammation.展开更多
Objective:To analyze the therapeutic effects of carteolol hydrochloride(CAR)eye drops combined with travoprost(TRA)eye drops in the treatment of open-angle glaucoma(OAG).Methods:A total of 72 OAG patients(87 eyes)hosp...Objective:To analyze the therapeutic effects of carteolol hydrochloride(CAR)eye drops combined with travoprost(TRA)eye drops in the treatment of open-angle glaucoma(OAG).Methods:A total of 72 OAG patients(87 eyes)hospitalized between October 2020 and October 2023 were randomly divided into two groups.The combination group received CAR and TRA eye drops,while the control group received CAR eye drops alone.Treatment outcomes were compared in terms of total efficacy rate,visual acuity,intraocular pressure,visual function indicators,hemodynamic parameters,and ocular surface damage indicators.Results:The combination group showed a higher total efficacy rate compared to the control group.After 3 months of treatment,the combination group had better visual acuity,lower intraocular pressure,higher mean sensitivity,lower mean defect,lower resistance index,and higher end-diastolic velocity and peak systolic velocity compared to the control group(P<0.05).Additionally,the combination group exhibited higher corneal fluorescein staining scores,shorter tear breakup time,and lower Schirmer tear test values compared to the control group(P<0.05).Conclusion:The combination of CAR and TRA eye drops improves visual acuity,effectively reduces intraocular pressure,enhances visual function,regulates ocular hemodynamics,and mitigates ocular surface damage in OAG patients,demonstrating superior therapeutic efficacy.展开更多
Purpose: To compare intraocular pressure (IOP)-lowering efficacy and safety of travoprost 0.004% and travoprost 0.004% and beta-blocker 0.5% fixed combination ophthalmic solution in patients with open-angle glaucoma a...Purpose: To compare intraocular pressure (IOP)-lowering efficacy and safety of travoprost 0.004% and travoprost 0.004% and beta-blocker 0.5% fixed combination ophthalmic solution in patients with open-angle glaucoma and ocular hypertension. Methods: In this prospective, multicentre clinical trial, 62 patients received travoprost 0.004% (n = 31) or travoprost 0.004% and beta-blocker 0.5% fixed combination (n = 31). Efficacy and safety were compared across treatment groups over 2 years. IOP reduction and adverse events were examined at 3, 6, 12 and 24 months for each group. Results: Mean IOP at the first visit in the travoprost 0.004% group was 26.4 (SD ± 2.1), and travoprost 0.004%/timolol 0.5% group was 26.3 (SD ± 2.1). Mean IOP after 24 months in the travoprost 0.004% group was 20.5 (SD ± 1.5) and travoprost 0.004%/timolol 0.5% group was 18.5 (SD ± 1.5). There were statistically significant differences in IOP in both eyes after third visit (after 1 year) and fourth visit (after 2 years). Conclusion: After 2 year of treatment, travoprost 0.004%/timolol 0.5% produced clinically relevant IOP reductions in patients with open-angle glaucoma or ocular hypertension that were greater than those produced by travoprost 0.004% alone.展开更多
Background Travoprost has been widely used for the treatment of patients with open-angle glaucoma （OAG） or ocular hypertension （OH）. The aim of this study was to evaluate the intraocular pressure （lOP） lowering ...Background Travoprost has been widely used for the treatment of patients with open-angle glaucoma （OAG） or ocular hypertension （OH）. The aim of this study was to evaluate the intraocular pressure （lOP） lowering efficacy of travoprost 0.004% monotherapy in patients previously treated with other topical hypotensive medications, and in previously untreated patients. Methods This open-label, 12-week study in 1651 adult patients with ocular hypertension or open-angle glaucoma who were untreated or required a change in therapy （due to either inadequate efficacy or safety issues） as judged by the investigator was conducted at 6 sites in China. Previously treated patients were instructed to discontinue their prior medications at the first visit. All the patients were dosed with travoprost 0.004% once-daily at 8 p.m. in both eyes for 12 weeks. Efficacy and safety evaluations were conducted at week 4 and 12. lOP measurements were performed at the same time of day at the follow-up visits. Results For patients transitioned to travoprost, mean lOP reductions from baseline in untreated and treated patients with different prior medications at week 12 were： latanoprost, （4.3±4.6） mmHg; β-blocker, （6.3±4.0） mmHg; α-agonist, （7.5±4.3） mmHg; topical carbonic anhydrase inhibitors, （8.0±4.9） mmHg. All mean lOP changes from baseline were statistically significant （P 〈0.001）. No treatment-related serious adverse events were reported in this study. Conclusions In patients treated with other hypotensive medications or untreated, the lOP reduction with travoprost was significant. The results of this study demonstrated the potential benefit of using travoprost as a replacement therapy in order to ensure adequate lOP control. Travoprost administered once daily was safe and well tolerated in patients with glaucoma or ocular hypertension.展开更多
Objective:The goal of this study was to see if travoprost and β-blockers improved MDA and SOD expression as well as neuroprotection in glaucoma mice.Methods:One hundred healthy SPF SD rats were randomly allocated int...Objective:The goal of this study was to see if travoprost and β-blockers improved MDA and SOD expression as well as neuroprotection in glaucoma mice.Methods:One hundred healthy SPF SD rats were randomly allocated into five groups:travoprost and β-blocker group,travoprost group,β-blocker group,model group and blank group,with 20 rats in each group.We created a glaucoma mouse model in which the blank group and the model group received the same volume of saline,the β-blocker group received β-blocker,the travoprost group received travoprost,and the travo Prost and β-blocker groups received travo Prost and βreceptor blockers.Retinal cell apoptosis level,intraocular pressure level,MDA and SOD levels were measured after drug administration.Results:The results showed that the levels of intraocular pressure,the apoptosis rate of optic nerve,SOD and MDA of retina in travoprost and β-blocker group,travoprost group,β-blocker group and model group were greater than those in blank group(P<0.05).In comparison to the model group,the intraocular pressure level,optic nerve apoptosis rate,and retinal MDA level in the travoprost and β-blocker group continued to fall,while the retinal SOD level was considerably elevated(P<0.05).The continuous application of travoprost and β-blocker resulted in a constant drop in intraocular pressure,optic nerve apoptosis rate and MDA level in the retina,whereas the SOD level was dramatically elevated(P<0.05).Conclusion:In glaucoma mice,travoprost in combination with a β-blocker can greatly increase MDA expression,SOD and neuroprotection.展开更多
目的:建立高效液相色谱法(high-performance liquid chromatography,HPLC)测定曲伏噻吗滴眼液中曲伏前列素有关物质。方法:采用Agilent SB-C18色谱柱(50 mm×2.1 mm,2.7μm);以磷酸溶液(取磷酸2.0 m L,加水稀释并定容至1000 m L,用...目的:建立高效液相色谱法(high-performance liquid chromatography,HPLC)测定曲伏噻吗滴眼液中曲伏前列素有关物质。方法:采用Agilent SB-C18色谱柱(50 mm×2.1 mm,2.7μm);以磷酸溶液(取磷酸2.0 m L,加水稀释并定容至1000 m L,用氢氧化钠溶液调节p H至3.0)为流动相A,乙腈为流动相B,洗脱梯度;流速为每分钟3.0 m L;柱温为30℃;检测波长为220 nm;进样体积100μL。结果:在该色谱条件下,曲伏前列素与各杂质均可良好分离;在酸、碱、氧化、高温和强光破坏条件下,曲伏前列素峰纯度合格,物料守恒。曲伏前列素、5,6-反式曲伏前列素和15-酮曲伏前列素分别在0.041~3.245μg/m L(r=1.0000)、0.040~3.229μg/m L(r=1.0000)、0.039~3.088μg/m L(r=0.9999)范围内线性关系良好,其最低检测限分别为0.020、0.020和0.020μg/m L;6份样品中5,6-反式曲伏前列素的含量相对标准偏差(relative standard deviatio,RSD)为0.2%(n=6),15-酮曲伏前列素的含量RSD为0.3%(n=6),重复性良好;对照品溶液和供试品溶液在室温条件下放置100h稳定,5,6-反式曲伏前列素的平均回收率为95.2%,相对标准偏差RSD为0.5%(n=9),15-酮曲伏前列素的平均回收率为92.7%,RSD为1.2%(n=9)该方法重现性好。结论:本方法简便、快速、准确。适用于检测曲伏噻吗滴眼液中的曲伏前列素有关物质。展开更多
目的:研究曲伏前列素与布林佐胺联合治疗原发性开角型青光眼(primary open angle glaucoma,POAG)、高眼压症(ocular hypertension,OHT)及抗青光眼术后高眼压的降眼压疗效及安全性。方法:将48例52眼POAG,OHT,抗青光眼术后高眼压的患者纳...目的:研究曲伏前列素与布林佐胺联合治疗原发性开角型青光眼(primary open angle glaucoma,POAG)、高眼压症(ocular hypertension,OHT)及抗青光眼术后高眼压的降眼压疗效及安全性。方法:将48例52眼POAG,OHT,抗青光眼术后高眼压的患者纳入为期2mo的前瞻性、单向性、开放性研究。经药物洗脱期测量眼压基线值。用药后2,4,8,12wk测量眼压、视力、视野,观察眼部症状、体征及全身副作用。计算12wk时眼压≤17mmHg患者百分比。结果:患者基线眼压28.08±2.50mmHg,4次随访眼压(17.12±1.42,16.71±1.55,16.13±1.52,16.12±1.49)mmHg,眼压下降均值10.35mmHg,最大下降率45%。用药后眼压与基线眼压比较差值有非常显著意义(P<0.01),用药12wk时,眼压≤17mmHg的患者占64%。常见的不良反应是结膜充血,偶见轻微烧灼感,轻度味觉异常等,对角膜、泪膜、视力、视野、血压、心率均未影响。结论:曲伏前列素与布林佐胺联合应用降眼压的效果明显,安全性好。联合用药,眼压≤17mmHg患者所占百分比显著。展开更多
目的:研究曲伏前列素滴眼液联合复方丹参片对老年青光眼患者房水屏障功能、MMP2及临床疗效的影响。方法:选择2012年5月-2015年10月期间在我院就诊的90例青光眼患者作为研究对象,随机分为实验组和对照组,实验组患者接受曲伏前列素滴眼液...目的:研究曲伏前列素滴眼液联合复方丹参片对老年青光眼患者房水屏障功能、MMP2及临床疗效的影响。方法:选择2012年5月-2015年10月期间在我院就诊的90例青光眼患者作为研究对象,随机分为实验组和对照组,实验组患者接受曲伏前列素滴眼液联合复方丹参片治疗,对照组患者接受曲伏前列素滴眼液治疗,比较两组患者治疗前后的平均眼压水平、房水屏障功能以及血清MMP2含量、MMP2/TIMP1比值。结果:治疗后1个月、2个月、3个月时,实验组患者的平均眼压水平(17.2±2.2 vs 19.7±3.1 mm Hg)、(17.0±2.8 vs 20.2±3.2 mm Hg)、(16.7±2.5 vs 18.2±3.5 mm Hg)均显著低于对照组(P<0.05);治疗后3个月时,实验组患者的房水闪辉值(18.3±2.8 vs 33.1±5.6 pc/ms)、房水细胞数以及血清MMP2含量(2.77±0.46 vs 4.02±0.72μg/L)及MMP2/TIMP1比例(0.48±0.07 vs 0.76±0.09)均显著低于对照组(P<0.05)。结论:曲伏前列素滴眼液联合复方丹参片治疗能够更为有效地降低眼压水平、改善房水屏障功能,可能与其降低MMP2含量有关。展开更多
文摘Purpose: This is a retrospective, comparative, head-to-head, not commissioned study about the efficacy of bimato-prost 0.03%, brimonidine 0.2%, brinzolamide 1%, dorzolamide 2%, and travoprost 0.004%/timolol 0.5%-fixed combinations in patients affected by na?ve open-angle glaucoma and IOP > 25 mmHg. Patients and Methods: Files from 70 patients (35 M, 35 F, mean age 69.52 y, S.D. 11.56, range: 37-87y) in our Glaucoma Service were retrospectively analyzed as long as 12 months. Every subgroup, including 14 age- and sex-matched patients, was allocated to 1 of the 5 groups of the fixed combinations monotherapy. Data recorded after 3 months follow-up were statistically analyzed by descriptive and ANOVA statistics as percentage of IOP reduction from baseline. Results: All the fixed combinations were effective in lowering IOP. The mean percentage reduction was: brimonidine/timolol 43.57%, dorzolamide/timolol 37.67%, bimatoprost/timolol 35.60%, travoprost/timolol 33.25% and brinzolamide/timolol 23.0%. The brimonidine/timolol fixed combination showed to be statistically significant more effective only than brinzolamide/timolol fixed combination (p = 0.001). Setting the α error to 5%, the power of the study is 26%, phi: 0.842. Discussion: In all this cohort of patients the target IOP was successfully achieved. All the fixed combinations used in this study had a very good profile of efficacy. Brimonidine, dorzolamide, bimatoprost and travoprost/timolol fixed combinations statistically significantly reduced the percentage of IOP from baseline (p = 0.001) more than brinzolamide/timolol fixed combination.
文摘A 38-year-old man with no history of uveitis developed neovascular glaucoma (NVG) due to proliferative diabetic retinopathy (PDR). He had a history of ocular surgery with placement of glaucoma drainage implants (GDI), ultrasonic phacoemulsification, and intraocular lens implantation in both eyes. The patient had undergone a recent pars plana vitrectomy with complete panretinal photocoagulation (PRP) to clear vitreous hemorrhage in his right eye. To prevent progressive optic nerve damage, travoprost was tentatively administered because of inadequate intraocular pressure (IOP) control following surgery, laser treatment, and topical administration of many other IOP-lowering drugs. The patient experienced severe vision loss associated with acute anterior and intermediate uveitis. We consider it a rare complication due to the NVG patient’s vulnerability following ocular surgery. Given that acute uveitis developed rapidly and required time to resolve, systemic corticosteroid treatment could be considered to accelerate the resolution of inflammation.
文摘Objective:To analyze the therapeutic effects of carteolol hydrochloride(CAR)eye drops combined with travoprost(TRA)eye drops in the treatment of open-angle glaucoma(OAG).Methods:A total of 72 OAG patients(87 eyes)hospitalized between October 2020 and October 2023 were randomly divided into two groups.The combination group received CAR and TRA eye drops,while the control group received CAR eye drops alone.Treatment outcomes were compared in terms of total efficacy rate,visual acuity,intraocular pressure,visual function indicators,hemodynamic parameters,and ocular surface damage indicators.Results:The combination group showed a higher total efficacy rate compared to the control group.After 3 months of treatment,the combination group had better visual acuity,lower intraocular pressure,higher mean sensitivity,lower mean defect,lower resistance index,and higher end-diastolic velocity and peak systolic velocity compared to the control group(P<0.05).Additionally,the combination group exhibited higher corneal fluorescein staining scores,shorter tear breakup time,and lower Schirmer tear test values compared to the control group(P<0.05).Conclusion:The combination of CAR and TRA eye drops improves visual acuity,effectively reduces intraocular pressure,enhances visual function,regulates ocular hemodynamics,and mitigates ocular surface damage in OAG patients,demonstrating superior therapeutic efficacy.
文摘Purpose: To compare intraocular pressure (IOP)-lowering efficacy and safety of travoprost 0.004% and travoprost 0.004% and beta-blocker 0.5% fixed combination ophthalmic solution in patients with open-angle glaucoma and ocular hypertension. Methods: In this prospective, multicentre clinical trial, 62 patients received travoprost 0.004% (n = 31) or travoprost 0.004% and beta-blocker 0.5% fixed combination (n = 31). Efficacy and safety were compared across treatment groups over 2 years. IOP reduction and adverse events were examined at 3, 6, 12 and 24 months for each group. Results: Mean IOP at the first visit in the travoprost 0.004% group was 26.4 (SD ± 2.1), and travoprost 0.004%/timolol 0.5% group was 26.3 (SD ± 2.1). Mean IOP after 24 months in the travoprost 0.004% group was 20.5 (SD ± 1.5) and travoprost 0.004%/timolol 0.5% group was 18.5 (SD ± 1.5). There were statistically significant differences in IOP in both eyes after third visit (after 1 year) and fourth visit (after 2 years). Conclusion: After 2 year of treatment, travoprost 0.004%/timolol 0.5% produced clinically relevant IOP reductions in patients with open-angle glaucoma or ocular hypertension that were greater than those produced by travoprost 0.004% alone.
文摘Background Travoprost has been widely used for the treatment of patients with open-angle glaucoma （OAG） or ocular hypertension （OH）. The aim of this study was to evaluate the intraocular pressure （lOP） lowering efficacy of travoprost 0.004% monotherapy in patients previously treated with other topical hypotensive medications, and in previously untreated patients. Methods This open-label, 12-week study in 1651 adult patients with ocular hypertension or open-angle glaucoma who were untreated or required a change in therapy （due to either inadequate efficacy or safety issues） as judged by the investigator was conducted at 6 sites in China. Previously treated patients were instructed to discontinue their prior medications at the first visit. All the patients were dosed with travoprost 0.004% once-daily at 8 p.m. in both eyes for 12 weeks. Efficacy and safety evaluations were conducted at week 4 and 12. lOP measurements were performed at the same time of day at the follow-up visits. Results For patients transitioned to travoprost, mean lOP reductions from baseline in untreated and treated patients with different prior medications at week 12 were： latanoprost, （4.3±4.6） mmHg; β-blocker, （6.3±4.0） mmHg; α-agonist, （7.5±4.3） mmHg; topical carbonic anhydrase inhibitors, （8.0±4.9） mmHg. All mean lOP changes from baseline were statistically significant （P 〈0.001）. No treatment-related serious adverse events were reported in this study. Conclusions In patients treated with other hypotensive medications or untreated, the lOP reduction with travoprost was significant. The results of this study demonstrated the potential benefit of using travoprost as a replacement therapy in order to ensure adequate lOP control. Travoprost administered once daily was safe and well tolerated in patients with glaucoma or ocular hypertension.
文摘Objective:The goal of this study was to see if travoprost and β-blockers improved MDA and SOD expression as well as neuroprotection in glaucoma mice.Methods:One hundred healthy SPF SD rats were randomly allocated into five groups:travoprost and β-blocker group,travoprost group,β-blocker group,model group and blank group,with 20 rats in each group.We created a glaucoma mouse model in which the blank group and the model group received the same volume of saline,the β-blocker group received β-blocker,the travoprost group received travoprost,and the travo Prost and β-blocker groups received travo Prost and βreceptor blockers.Retinal cell apoptosis level,intraocular pressure level,MDA and SOD levels were measured after drug administration.Results:The results showed that the levels of intraocular pressure,the apoptosis rate of optic nerve,SOD and MDA of retina in travoprost and β-blocker group,travoprost group,β-blocker group and model group were greater than those in blank group(P<0.05).In comparison to the model group,the intraocular pressure level,optic nerve apoptosis rate,and retinal MDA level in the travoprost and β-blocker group continued to fall,while the retinal SOD level was considerably elevated(P<0.05).The continuous application of travoprost and β-blocker resulted in a constant drop in intraocular pressure,optic nerve apoptosis rate and MDA level in the retina,whereas the SOD level was dramatically elevated(P<0.05).Conclusion:In glaucoma mice,travoprost in combination with a β-blocker can greatly increase MDA expression,SOD and neuroprotection.
文摘目的:建立高效液相色谱法(high-performance liquid chromatography,HPLC)测定曲伏噻吗滴眼液中曲伏前列素有关物质。方法:采用Agilent SB-C18色谱柱(50 mm×2.1 mm,2.7μm);以磷酸溶液(取磷酸2.0 m L,加水稀释并定容至1000 m L,用氢氧化钠溶液调节p H至3.0)为流动相A,乙腈为流动相B,洗脱梯度;流速为每分钟3.0 m L;柱温为30℃;检测波长为220 nm;进样体积100μL。结果:在该色谱条件下,曲伏前列素与各杂质均可良好分离;在酸、碱、氧化、高温和强光破坏条件下,曲伏前列素峰纯度合格,物料守恒。曲伏前列素、5,6-反式曲伏前列素和15-酮曲伏前列素分别在0.041~3.245μg/m L(r=1.0000)、0.040~3.229μg/m L(r=1.0000)、0.039~3.088μg/m L(r=0.9999)范围内线性关系良好,其最低检测限分别为0.020、0.020和0.020μg/m L;6份样品中5,6-反式曲伏前列素的含量相对标准偏差(relative standard deviatio,RSD)为0.2%(n=6),15-酮曲伏前列素的含量RSD为0.3%(n=6),重复性良好;对照品溶液和供试品溶液在室温条件下放置100h稳定,5,6-反式曲伏前列素的平均回收率为95.2%,相对标准偏差RSD为0.5%(n=9),15-酮曲伏前列素的平均回收率为92.7%,RSD为1.2%(n=9)该方法重现性好。结论:本方法简便、快速、准确。适用于检测曲伏噻吗滴眼液中的曲伏前列素有关物质。
文摘目的:研究曲伏前列素与布林佐胺联合治疗原发性开角型青光眼(primary open angle glaucoma,POAG)、高眼压症(ocular hypertension,OHT)及抗青光眼术后高眼压的降眼压疗效及安全性。方法:将48例52眼POAG,OHT,抗青光眼术后高眼压的患者纳入为期2mo的前瞻性、单向性、开放性研究。经药物洗脱期测量眼压基线值。用药后2,4,8,12wk测量眼压、视力、视野,观察眼部症状、体征及全身副作用。计算12wk时眼压≤17mmHg患者百分比。结果:患者基线眼压28.08±2.50mmHg,4次随访眼压(17.12±1.42,16.71±1.55,16.13±1.52,16.12±1.49)mmHg,眼压下降均值10.35mmHg,最大下降率45%。用药后眼压与基线眼压比较差值有非常显著意义(P<0.01),用药12wk时,眼压≤17mmHg的患者占64%。常见的不良反应是结膜充血,偶见轻微烧灼感,轻度味觉异常等,对角膜、泪膜、视力、视野、血压、心率均未影响。结论:曲伏前列素与布林佐胺联合应用降眼压的效果明显,安全性好。联合用药,眼压≤17mmHg患者所占百分比显著。
文摘目的:研究曲伏前列素滴眼液联合复方丹参片对老年青光眼患者房水屏障功能、MMP2及临床疗效的影响。方法:选择2012年5月-2015年10月期间在我院就诊的90例青光眼患者作为研究对象,随机分为实验组和对照组,实验组患者接受曲伏前列素滴眼液联合复方丹参片治疗,对照组患者接受曲伏前列素滴眼液治疗,比较两组患者治疗前后的平均眼压水平、房水屏障功能以及血清MMP2含量、MMP2/TIMP1比值。结果:治疗后1个月、2个月、3个月时,实验组患者的平均眼压水平(17.2±2.2 vs 19.7±3.1 mm Hg)、(17.0±2.8 vs 20.2±3.2 mm Hg)、(16.7±2.5 vs 18.2±3.5 mm Hg)均显著低于对照组(P<0.05);治疗后3个月时,实验组患者的房水闪辉值(18.3±2.8 vs 33.1±5.6 pc/ms)、房水细胞数以及血清MMP2含量(2.77±0.46 vs 4.02±0.72μg/L)及MMP2/TIMP1比例(0.48±0.07 vs 0.76±0.09)均显著低于对照组(P<0.05)。结论:曲伏前列素滴眼液联合复方丹参片治疗能够更为有效地降低眼压水平、改善房水屏障功能,可能与其降低MMP2含量有关。
